recent
identifi
three
molecul
tiloron
quinacrin
pyronaridin
tetraphosph
demonstr
efficaci
mous
model
infect
mouseadapt
ebola
viru
ebov
model
diseas
similar
vitro
inhibit
ebola
pseudoviru
vsvebovgp
suggest
interfer
viral
entri
use
machin
learn
model
predict
lysosomotrop
compound
evalu
abil
inhibit
via
lysosomotrop
mechan
vitro
demonstr
vitro
pyronaridin
tetraphosph
inhibitor
lysotrack
accumul
lysosom
ic
evalu
synergi
pyronaridin
artesun
use
combin
treat
malaria
artesun
found
lysosomotrop
activ
vitro
combin
effect
ebov
inhibit
shown
addit
may
repres
uniqu
exampl
repurpos
combin
product
anoth
diseas
outbreak
ebola
viru
ebov
diseas
evd
africa
come
great
human
financi
cost
exampl
outbreak
kill
estim
result
econom
damag
recent
outbreak
democrat
republ
congo
kill
peopl
even
approv
vaccin
prevent
evd
still
urgent
need
advanc
develop
filovirusspecif
antivir
therapeut
clinic
trial
investig
zmapp
monoclon
antibodi
cocktail
remdesivir
small
molecul
monoclon
combin
monoclon
antibodi
combin
result
show
antibodi
overal
statist
similar
surviv
rate
respect
unfortun
zmapp
remdesivir
less
effect
surviv
rate
respect
remdesivir
show
statist
signific
clinic
efficaci
search
antivir
small
molecul
continu
effort
repurpos
drug
treatment
evd
develop
bayesian
machin
learn
ml
approach
set
antiebov
activ
molecul
identifi
viral
pseudotyp
entri
assay
confirm
ebov
replic
assay
ebov
ml
model
enabl
us
virtual
screen
sever
thousand
compound
identifi
three
activ
compound
ebov
tiloron
quinacrin
pyronaridin
tetraphosph
three
molecul
inhibit
ebov
hela
cell
demonstr
signific
vivo
activ
mouseadapt
ebov
maebov
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doiorg
doi
biorxiv
preprint
efficaci
model
guinea
pig
model
ebov
infect
compound
also
inhibit
replic
multipl
strain
ebov
marburg
viru
marv
trend
compound
activ
ebov
marv
demonstr
analysi
previous
publish
data
reveal
vitro
inhibit
ic
correl
figur
date
determin
mechan
antivir
compound
identifi
previous
evalu
pyronaridin
tiloron
quinacrin
vitro
antiebov
activ
zair
strain
type
ifndefici
vero
cell
line
antivir
activ
observ
concentr
cytotox
concentr
hela
cell
three
drug
demonstr
select
observ
support
hypothesi
antivir
activ
could
partial
act
type
ifnrel
innat
immun
pathway
also
test
combin
pyronaridin
tiloron
hela
cell
evalu
data
braid
model
suggest
like
synergist
base
publish
data
tiloron
quinacrin
well
known
lysosomotrop
agent
suspect
may
also
import
addit
pyronaridin
use
antimalari
combin
artesun
previous
determin
artesun
also
micromolar
vitro
inhibitori
activ
ebov
assess
whether
pyronaridin
accumul
lysosom
effect
artesun
activ
metabolit
dihydroartemisinin
ebov
combin
pyronaridin
vitro
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doiorg
pyronaridin
tetraphosph
sigmaaldrich
pyronaridin
tetraphosph
tiloron
quinacrin
also
test
use
niaid
dmid
servic
repres
sever
virus
use
human
cell
gener
method
describ
previous
assay
central
softwar
previous
describ
use
sourc
code
manag
system
git
gather
store
structureact
dataset
previou
publish
lysosomotrop
assay
nadanaciva
et
al
use
basi
follow
work
human
metastat
mammari
gland
cell
line
obtain
american
type
cultur
collect
atcc
cell
grown
eagl
minimum
essenti
medium
corn
supplement
fetal
bovin
serum
gibco
unitml
penicillin
streptomycin
corn
humidifi
incub
co
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doiorg
lysosomotrop
assay
cell
seed
black
wall
clear
bottom
plate
cellswel
ul
growth
media
incub
hour
h
cell
treat
drug
dilut
initi
test
concentr
addit
seri
test
dilut
final
base
solubl
restrict
compound
stock
either
solubil
dmso
tiloron
quinacrin
artesun
water
pyronaridin
chloroquin
control
well
includ
cell
treat
dmso
water
start
assay
appropri
compound
stock
control
ad
use
biomek
nx
p
beckman
coulter
incub
co
hour
lysotrack
red
nm
thermofish
ad
incub
min
follow
wash
phosphat
buffer
salin
pb
cell
immedi
fix
formalin
room
temperatur
min
cell
stain
hoechst
sigmaaldrich
pb
min
room
temperatur
follow
cell
stain
wash
pb
experiment
run
test
seri
compound
triplic
repeat
two
differ
day
compound
seri
multipl
dmso
water
control
per
plate
imag
done
use
cellinsight
high
content
screen
platform
thermo
scientif
object
fluoresc
measur
hoechst
nuclei
lysotrack
red
lysosom
channel
respect
total
field
captur
well
analysi
nuclei
identifi
circular
mask
extend
pixel
repres
cell
total
intens
fluoresc
signal
lysotrack
red
within
mask
area
use
repres
lysosom
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
stain
cell
data
normal
control
analyz
graphpad
prism
version
error
bar
doserespons
curv
repres
sem
replic
cell
seed
white
wall
clear
bottom
plate
cellswel
growth
media
incub
h
start
assay
compound
stock
control
ad
use
biomek
nx
p
incub
co
hour
follow
compound
incub
celltiterglo
promega
ad
plate
shaken
orbit
shaker
rpm
min
read
envis
multilabel
reader
perkinelm
experi
repeat
triplic
data
analyz
graphpad
prism
version
error
bar
doserespons
curv
repres
sem
replic
luminesc
read
spark
plate
reader
tecan
us
morrisvil
nc
signal
treat
infect
well
normal
uninfect
control
well
measur
percent
rel
untreat
infect
well
nonlinear
regress
analysi
perform
inhibitori
concentr
ec
calcul
fit
curv
log
agonist
versu
respons
variabl
slope
constraint
remain
exceed
graphpad
softwar
version
la
jolla
ca
ebov
drug
screen
assay
perform
three
replic
drug
concentr
error
bar
doserespons
curv
repres
sem
replic
quantit
drug
toxic
hela
cell
mock
infect
viru
treat
drug
dilut
condit
infect
cell
h
cell
viabil
measur
use
celltit
glo
luminesc
cell
viabil
assay
kit
accord
manufactur
protocol
promega
madison
wi
braid
analysi
servic
calcul
synergi
fit
data
sevenvari
function
variabl
repres
quantit
synergi
valu
impli
antagon
impli
addit
impli
synergi
addit
refer
strong
synergi
correspond
mild
synergi
correspond
mild
antagon
correspond
strong
antagon
correspond
assess
combin
inhibitori
effect
pyronaridin
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
artesunatedihydroartemisinin
ebov
synergist
addit
antagonist
analyz
checkboard
assay
pair
drug
variou
combin
concentr
hela
huh
cell
note
inhibit
data
toxic
concentr
consist
cell
death
remov
analysi
inclus
consist
individu
combin
experi
concentr
pyronaridin
exceed
cc
ie
concentr
hela
cell
toxic
data
retain
braid
analysi
synergyfind
analysi
servic
similarli
calcul
degre
combin
synergi
antagon
compar
observ
drug
combin
respons
expect
respons
assum
interact
two
drug
score
calcul
use
loew
refer
addit
mode
threshold
defin
good
synergi
score
variabl
program
develop
suggest
synergi
score
near
give
limit
confid
synergi
antagon
score
expect
antagonist
synergist
respect
pyronaridin
quinacrin
tiloron
previous
demonstr
activ
ebov
hela
cell
vero
cell
show
select
cell
line
concentr
test
may
due
high
cytotox
insuffici
rang
concentr
test
cell
line
tabl
bayesian
machin
learn
model
compound
class
lysosomotrop
gener
publish
data
use
assay
central
tm
cross
valid
roc
figur
addit
model
statist
suggest
model
potenti
use
score
compound
predict
lysosom
accumul
tabl
tiloron
pyronaridin
artesun
use
prospect
test
set
compound
correctli
predict
tiloron
pyronaridin
predict
lysosomotrop
artesun
predict
lysosomotrop
pyronaridin
tetraphosph
found
potent
inhibitor
lysotrack
accumul
lysosom
vitro
ic
contrast
artesun
show
appreci
inhibit
lysotrack
figur
tiloron
ic
chloroquin
ic
final
quinacrin
ic
less
potent
inhibitor
lysotrack
accumul
lysosom
vitro
figur
braid
analysi
figur
pyronaridin
artesun
vitro
inhibit
data
checkerboard
assay
indic
addit
molecul
hela
cell
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
artesun
amelior
toxic
pyronaridin
checkboard
assay
therefor
indirectli
potenti
pyronaridin
nonlinear
regress
curv
fit
hill
equat
artesun
control
huh
cell
suggest
plateau
inhibit
figur
therefor
combin
data
celllin
pyronaridineartesun
pair
includ
analysi
pyronaridin
dha
similarli
show
addit
effect
hela
huh
cell
parallel
reduct
toxic
base
braid
analysi
figur
secondari
analysi
use
synergyfind
figur
also
suggest
combin
indirectli
potenti
pyronaridin
hela
cell
huh
cell
interpret
ambigu
figur
within
last
year
seen
two
major
evd
outbreak
africa
led
renew
effort
develop
treatment
viru
activ
inact
sever
vitro
high
throughput
drug
screen
use
develop
comput
model
predict
antiebov
activ
compound
recent
combin
approv
drug
found
studi
suggest
synergist
combin
date
none
mani
effort
ebov
result
clinic
antivir
candid
sever
small
molecul
antivir
fell
hurdl
anim
model
specif
transit
mous
guinea
pig
model
compound
fail
show
vivo
efficaci
ebov
follow
welltrodden
rout
includ
chloroquin
azithromycin
amiodaron
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
discuss
previous
may
due
differ
drug
metabol
make
model
inappropri
ebov
effort
improv
effici
cost
effect
ebov
drug
discoveri
involv
effort
identifi
sever
molecul
use
ml
progress
vitro
vivo
test
also
previous
use
ml
model
predict
vitro
efficaci
drug
test
ebov
mechan
three
compound
ebov
unknown
other
demonstr
compound
physicochem
properti
basic
pka
clogp
tend
lysosomotrop
accumul
lysosom
taken
ml
approach
predict
potenti
lysosomotrop
mechan
use
publish
vitro
data
along
molecular
fingerprint
bayesian
algorithm
perform
sever
vitro
studi
valid
predict
abil
model
well
infer
potenti
mechan
one
ebov
drug
pyronaridin
clearli
potent
lysosomotrop
agent
molecul
test
strong
correl
publish
antiebov
activ
lysosomotrop
properti
tabl
larg
number
drug
compound
consid
activ
model
research
identifi
whether
previous
test
ebov
marv
either
psuedovirusvlp
compet
viru
inhibit
assay
compound
test
previous
inhibit
virus
ac
almost
nm
low
rang
certainli
comprehens
list
lysosomotrop
compound
strongli
support
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doiorg
doi
biorxiv
preprint
notion
lysosomotrop
characterist
directli
relat
antivir
activ
compound
within
model
artesun
also
similarli
activ
ebov
found
share
physiolog
characterist
initi
combin
two
drug
form
avoid
drug
resist
plasmodium
parasit
caus
agent
malaria
extens
review
combin
two
molecul
addit
inhibit
ebov
replic
vitro
reduc
cytotox
compar
individu
treatment
figur
previou
work
suggest
possibl
identifi
pair
drug
block
ebov
infect
vitro
via
methodolog
use
current
studi
implic
outsid
ebov
increas
interest
antivir
test
particular
heavi
focu
chloroquin
hydroxychloroquin
shown
low
micromolar
activ
vitro
viru
pyronaridin
recent
also
shown
limit
activ
vero
cell
vero
cell
may
appropri
human
cell
test
compound
pyronaridin
low
vitro
select
index
high
vivo
antivir
activ
base
previou
find
leav
distinct
possibl
underestim
pyronaridin
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doiorg
doi
biorxiv
preprint
antivir
inhibit
potenti
current
data
also
suggest
test
artesun
versu
addit
virus
well
combin
pyronaridin
frequent
singl
drug
repurpos
new
use
knowledg
preced
two
drug
combin
repurpos
indic
previous
estim
dose
use
treat
malaria
patient
may
benefici
effect
ebov
patient
indic
potenti
direct
repurpos
without
need
chang
dose
rout
formul
experi
insight
gain
discoveri
antivir
properti
pyronaridin
tiloron
quinacrin
propos
ml
approach
could
optim
ad
addit
ml
model
lysosomotrop
mechan
describ
would
enabl
us
creat
comput
pipelin
identifi
new
antivir
rapidli
could
lysosomotrop
properti
henc
direct
antivir
mechan
action
investig
molecul
mechan
may
also
util
broadspectrum
antivir
need
counter
flare
up
virus
like
ebov
marv
potenti
pandem
trl
employe
collabor
pharmaceut
inc
collabor
pharmaceut
inc
obtain
fda
orphan
drug
design
pyronaridin
tiloron
quinacrin
use
ebola
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
natur
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doiorg
